Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 59

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Paroxysmal nocturnal haemoglobinuria16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Hyperkalaemia+2

Not recruiting

Study on Sodium Zirconium Cyclosilicate for Patients with Chronic Kidney Disease Stages 3b and 4 to Allow More Fruits and Vegetables in Their Diet

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Cerebral amyloid angiopathy

Not recruiting

Study on the Safety and Effects of Acetylcysteine Amide for Patients Aged 12 and Over with Hereditary Cystatin C Amyloid Angiopathy

InvestigationalNo placebo
Countries:IcelandIceland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Acetylcysteine Amide
  • Sponsor:Arctic Therapeutics ehf.

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Skin ulcer

Not recruiting

Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells
  • Sponsor:Rheacell GmbH & Co. KG

Arteriosclerosis+1

Not recruiting

Study on the Safety and Effects of INZ-701 for Infants with ENPP1 or ABCC6 Deficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Cardiogenic shock

Not recruiting

Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken

Pulmonary arterial hypertension

Not recruiting

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Primary hyperaldosteronism

Not recruiting

Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga)
  • Sponsor:Assistance Publique Hopitaux De Paris

Atrial fibrillation+1

Not recruiting

Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Amsterdam UMC Stichting

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Migraine

Not recruiting

Study on Lasmiditan for Treating Migraine in Children Aged 6 to 17

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Lasmiditan
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.